Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo

Antiviral Research

Volumn 99, Issue 2, 2013, Pages 100-107

  Takano, Tomomi ^a   Katoh, Yasuichiroh ^a   Doki, Tomoyoshi ^a   Hohdatsu, Tsutomu ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Chloroquine; Feline coronavirus; Feline infectious peritonitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CHLOROQUINE; COMPLEMENTARY DNA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AUTOPSY; CAT; CONTROLLED STUDY; CORONAVIRUS INFECTION; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MONOCYTE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PYOGRANULOMA; RNA ISOLATION; VIRUS INHIBITION;

CHLOROQUINE; FELINE CORONAVIRUS; FELINE INFECTIOUS PERITONITIS;

ALANINE TRANSAMINASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CAT DISEASES; CATS; CELL LINE; CHLOROQUINE; CORONAVIRUS, FELINE; FELINE INFECTIOUS PERITONITIS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

FELIDAE; FELINE CORONAVIRUS; FELINE INFECTIOUS PERITONITIS VIRUS; FELIS SILVESTRIS;

EID: 84878695753     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.016     Document Type: Article

References (38)

1. Aderounmu A.F., Fleckenstein L. Pharmacokinetics of chloroquine diphosphate in the dog. J. Pharmacol. Exp. Ther. 1983, 226:633-639.
2. Aderounmu A.F., Salako L.A., Lindström B., Walker O., Ekman L. Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans. Br. J. Clin. Pharmacol. 1986, 22:559-564.
3. Balzarini J., Keyaerts E., Vijgen L., Vandermeer F., Stevens M., De Clercq E., Egberink H., Van Ranst M. Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. J. Antimicrob. Chemother. 2006, 57:472-481.
4. Barlough J.E., Shacklett B.L. Antiviral studies of feline infectious peritonitis virus in vitro. Vet. Rec. 1994, 1135:177-179.
5. Corapi W.V., Olsen C.W., Scott F.W. Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J. Virol. 1992, 66:6695-6705.
6. Dewerchin H.L., Cornelissen E., Nauwynck H.J. Replication of feline coronaviruses in peripheral blood monocytes. Arch. Virol. 2005, 150:2483-2500.
7. Hartmann K., Ritz S. Treatment of cats with feline infectious peritonitis. Vet. Immunol. Immunopathol. 2008, 123:172-175.
8. Ducharme J., Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. 1996, 31:257-274.
9. de Groot-Mijnes J.D., van Dun J.M., van der Most R.G., de Groot R.J. Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease. J. Virol. 2005, 79:1036-1044.
10. Gustafsson L.L., Walker O., Alván G., Beermann B., Estevez F., Gleisner L., Lindström B., Sjöqvist F. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 1983, 15:471-479.
11. Hartmann K., Kuffer M. Karnofsky's score modified for cats. Eur. J. Med. Res. 1998, 1998(3):95-98.
12. Hohdatsu T., Nakamura M., Ishizuka Y., Yamada H., Koyama H. A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies. Arch. Virol. 1991, 120:207-217.
13. Hohdatsu T., Yamada H., Ishizuka Y., Koyama H. Enhancement and neutralization of feline infectious peritonitis virus infection in feline macrophages by neutralizing monoclonal antibodies recognizing different epitopes. Microbiol. Immunol. 1993, 37:499-504.
14. Hsieh L.E., Lin C.N., Su B.L., Jan T.R., Chen C.M., Wang C.H., Lin D.S., Lin C.T., Chueh L.L. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antiviral Res. 2010, 88:25-30.
15. Jang C.H., Choi J.H., Byun M.S., Jue D.M. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 2006, 45:703-710.
16. Karres I., Kremer J.P., Dietl I., Steckholzer U., Jochum M., Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am. J. Physiol. 1998, 274:R1058-R1064.
17. Kim Y., Mandadapu S.R., Groutas W.C., Chang K.O. Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antiviral Res. 2012, pii: S0166-3542(12)00260-4. 10.1016/j.antiviral.2012.11.005.
18. Kono M., Tatsumi K., Imai A.M., Saito K., Kuriyama T., Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008, 77:150-152.
19. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J., SARS Working Group A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348:1953-1966.
20. Landewé R.B., Goei Thè H.S., van Rijthoven A.W., Breedveld F.C., Dijkmans B.A. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum. 1994, 37:637-643.
21. Lesiak A., Narbutt J., Sysa-Jedrzejowska A., Lukamowicz J., McCauliffe D.P., Wózniacka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 2010, 19:683-688.
22. Müller M.A., Raj V.S., Muth D., Meyer B., Kallies S., Smits S.L., Wollny R., Bestebroer T.M., Specht S., Suliman T., Zimmermann K., Binger T., Eckerle I., Tschapka M., Zaki A.M., Osterhaus A.D., Fouchier R.A., Haagmans B.L., Drosten C. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012, 3. pii: e00473-12. 10.1128/mBio.00473-12.
23. Murray S.M., Down C.M., Boulware D.R., Stauffer W.M., Cavert W.P., Schacker T.W., Brenchley J.M., Douek D.C. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J. Virol. 2010, 84:12082-12086.
24. Olsen C.W., Corapi W.V., Ngichabe C.K., Baines J.D., Scott F.W. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J. Virol. 1992, 66:956-965.
25. Pallister J., Middleton D., Crameri G., Yamada M., Klein R., Hancock T.J., Foord A., Shiell B., Michalski W., Broder C.C., Wang L.F. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J. Virol. 2009, 83:11979-11982.
26. Pedersen N.C. A review of feline infectious peritonitis virus infection: 1963-2008. J. Feline Med. Surg. 2009, 11:225-258.
27. Pedersen N.C., Boyle J.F. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am. J. Vet. Res. 1980, 41:868-876.
28. Regan A.D., Cohen R.D., Whittaker G.R. Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. Virology 2009, 384:135-143.
29. Ritz S., Egberink H., Hartmann K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J. Vet. Intern. Med. 2007, 21:1193-1197.
30. Savarino A., Boelaert J.R., Cassone A., Majori G., Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect. Dis. 2003, 3:722-727.
31. Takano T., Azuma N., Satoh M., Toda A., Hashida Y., Satoh R., Hohdatsu T. Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of granulomatous lesions. Arch. Virol. 2009, 154:775-781.
32. Takano T., Hohdatsu T., Hashida Y., Kaneko Y., Tanabe M., Koyama H. A "possible" involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet. Microbiol. 2007, 119:121-131.
33. Takano T., Hohdatsu T., Toda A., Tanabe M., Koyama H. TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-induced macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 2007, 364:64-72.
34. Takano T., Katada Y., Moritoh S., Ogasawara M., Satoh K., Satoh R., Tanabe M., Hohdatsu T. Analysis of the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection: aminopeptidase N is not important and a process of acidification of the endosome is necessary. J. Gen. Virol. 2008, 89:1025-1029.
35. Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., Seidah N.G., Nichol S.T. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005, 2:69.
36. Vigerust D.J., McCullers J.A. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir. Viruses 2007, 1:189-192.
37. Weber S.M., Levitz S.M. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J. Immunol. 2000, 165:1534-1540.
38. Yan Y., Zou Z., Sun Y., Li X., Xu K.F., Wei Y., Jin N., Jiang C. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2012, 10.1038/cr.2012.165.